- Home
- APPS vs NGEN Comparison
APPS vs NGEN Comparison
Compare APPS & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | APPS | NGEN |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | Canada |
| Employees | N/A | 14 |
| Industry | Multi-Sector Companies | |
| Sector | Miscellaneous | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 346.5M | 337.4M |
| IPO Year | 2012 | N/A |
Fundamental Metrics
Financial Performance| Metric | APPS | NGEN |
|---|---|---|
| Price | $3.89 | $3.73 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $6.25 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 1.9M | 208.7K |
| Earning Date | 06-15-2026 | 04-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 78.61 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $103,569,000.00 | N/A |
| Revenue This Year | $15.60 | N/A |
| Revenue Next Year | $11.34 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 38.55 | N/A |
| 52 Week Low | $2.74 | $3.51 |
| 52 Week High | $8.28 | $5.93 |
Technical Indicators
Market Signals| Indicator | APPS | NGEN |
|---|---|---|
| Relative Strength Index (RSI) | 60.38 | 42.14 |
| Support Level | $3.78 | $3.65 |
| Resistance Level | $4.07 | $4.44 |
| Average True Range (ATR) | 0.23 | 0.21 |
| MACD | 0.06 | -0.03 |
| Stochastic Oscillator | 76.13 | 20.36 |
Price Performance
Historical ComparisonAbout APPS Digital Turbine Inc.
Digital Turbine Inc is an independent mobile growth platform. It offers end-to-end products and solutions to all participants in the mobile application ecosystem, enabling brand discovery and advertising, user acquisition and engagement, and operational efficiency for advertisers. Its operating segments are On Device Solutions and App Growth Platform.
About NGEN NervGen Pharma Corp. Common stock
NervGen Pharma Corp is a clinical-stage biotech company. The company's principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291 and NVG-300.